Catheter ablation demonstrated limited benefit in Lamin A/C (LMNA)-related cardiomyopathy. The Journal of Cardiovascular Electrophysiology published a systematic review and single-arm meta-analysis including 62 individuals with pathogenic LMNA variants from seven studies (mean age 53.2 ± 9.7 years; 85% male). Most patients (93%) underwent combined endocardial and epicardial ablation, and 88% already had an ICD at baseline due to their high arrhythmic risk.

Acute procedural success was achieved in 37%. However, long-term rhythm control was poor. VT recurred in 91% of patients over a median follow-up of 26 months, and 28% required repeat ablation. Outcomes remained unfavorable despite intervention. All-cause mortality was 54%, predominantly cardiac (51%), and 14% progressed to heart transplantation.

These findings indicate that catheter ablation alone offers limited durable VT suppression in LMNA cardiomyopathy. ICD therapy remains essential, and further investigation into genotype-directed and molecularly targeted strategies is needed to improve survival in this high-risk population.